https://www.worldpharmanews.com/bayer/6215-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbio-s-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics
Recombinant adeno-associated virus (rAAV) technology pioneered by AskBio's Dr. Jude Samulski is key...
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA's approval of a new...
adeno associated virusjude samulskirecombinantraavtechnology